Anti-EDEM2/ C20orf31/ C20orf49 functional antibody
Anti-EDEM2/ C20orf31/ C20orf49 functional antibody for cell culture, ELISA & in-vivo assay
Go to EDEM2/EDEM2 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
Product information
Catalog No. | Product Name | Species Reactivity |
---|---|---|
GM-Tg-hg-SE1428-Ab-1/ GM-Tg-hg-SE1428-Ab-2 | Anti-Human EDEM2 monoclonal antibody | Human |
GM-Tg-rg-SE1428-Ab-1/ GM-Tg-rg-SE1428-Ab-2 | Anti-Rat EDEM2 monoclonal antibody | Rat |
GM-Tg-mg-SE1428-Ab-1/ GM-Tg-mg-SE1428-Ab-2 | Anti-Mouse EDEM2 monoclonal antibody | Mouse |
GM-Tg-cynog-SE1428-Ab-1/ GM-Tg-cynog-SE1428-Ab-2 | Anti-Cynomolgus/ Rhesus macaque EDEM2 monoclonal antibody | Cynomolgus/ Rhesus macaque |
GM-Tg-felg-SE1428-Ab-1/ GM-Tg-felg-SE1428-Ab-2 | Anti-Feline EDEM2 monoclonal antibody | Feline |
GM-Tg-cang-SE1428-Ab-1/ GM-Tg-cang-SE1428-Ab-2 | Anti-Canine EDEM2 monoclonal antibody | Canine |
GM-Tg-bovg-SE1428-Ab-1/ GM-Tg-bovg-SE1428-Ab-2 | Anti-Bovine EDEM2 monoclonal antibody | Bovine |
GM-Tg-equg-SE1428-Ab-1/ GM-Tg-equg-SE1428-Ab-2 | Anti-Equine EDEM2 monoclonal antibody | Equine |
Size: 1mg | 10mg | 100mg
Product Description
Catalog No. | GM-Tg-hg-SE1428-Ab-1/ GM-Tg-hg-SE1428-Ab-2; GM-Tg-rg-SE1428-Ab-1/ GM-Tg-rg-SE1428-Ab-2; GM-Tg-mg-SE1428-Ab-1/ GM-Tg-mg-SE1428-Ab-2; GM-Tg-cynog-SE1428-Ab-1/ GM-Tg-cynog-SE1428-Ab-2; GM-Tg-felg-SE1428-Ab-1/ GM-Tg-felg-SE1428-Ab-2; GM-Tg-cang-SE1428-Ab-1/ GM-Tg-cang-SE1428-Ab-2; GM-Tg-bovg-SE1428-Ab-1/ GM-Tg-bovg-SE1428-Ab-2; GM-Tg-equg-SE1428-Ab-1/ GM-Tg-equg-SE1428-Ab-2 |
Products Name | Anti-EDEM2 monoclonal antibody |
Format | mab |
Target Name | EDEM2 |
Protein Sub-location | Secreted Protein/Potential Cytokines |
Category of antibody | FACS/Biofunctional Antibody |
Derivation (species) | Mouse |
CH1+2+3 Isotype (Receptor identification) | IgG |
Type of Light Chain (VD-LC) | N/A |
Expression platform | Mammalian Expression |
Bioactivity validation | Binding affinity is validated by ELISA with recombinant soluble protein antigen. The biofunction of antibodies are validated with in-vitro assay (IC50 or EC50 TBD). |
Tag | Fc |
Products description | Pre-made anti-EDEM2 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
Formulation | Lyophilized from sterile PBS, PH 7.4 |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
Category | Cat No. | Products Name |
Target Antigen | GM-Tg-g-SE1428-Ag-1 | Recombinant multi-species EDEM2/ C20orf31/ C20orf49 protein |
Target information
Target ID | GM-SE1428 |
Target Name | EDEM2 |
Gene ID | 55741,108687,296304,706150,100054608 |
Gene Symbol and Synonyms | 9530090G24Rik,bA4204.1,C20orf31,C20orf49,EDEM2,RGD1303074 |
Uniprot Accession | Q9BV94 |
Uniprot Entry Name | EDEM2_HUMAN |
Protein Sub-location | Secreted Protein/Potential Cytokines |
Category | |
Disease | N/A |
Gene Ensembl | ENSG00000088298 |
Target Classification | N/A |
The target: EDEM2, gene name: EDEM2, also named as C20orf31, C20orf49, bA4204.1. In the endoplasmic reticulum (ER), misfolded proteins are retrotranslocated to the cytosol and degraded by the proteasome in a process known as ER-associated degradation (ERAD). EDEM2 belongs to a family of proteins involved in ERAD of glycoproteins (Mast et al., 2005 [PubMed 15537790]).[supplied by OMIM, Mar 2008].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.